HDL quality and functionality: What can proteins and genes predict?

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 4, 2014, Pages 521-532

  Karavia, Eleni A ^a   Zvintzou, Evangelia ^a   Petropoulou, Peristera Ioanna ^a   Xepapadaki, Eva ^a   Constantinou, Caterina ^a   Kypreos, Kyriakos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

apolipoproteins; function; HDL; HDL modifying enzymes; structure

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOPROTEIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; ENDOTHELIAL LIPASE; ENZYME; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID TRANSFER PROTEIN; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PROTEIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ATHEROPROTECTION; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CELL PROTECTION; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); CORONARY RISK; DISEASE MARKER; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEART PROTECTION; HIGH DENSITY LIPOPROTEIN FUNCTION; HIGH DENSITY LIPOPROTEIN QUALITY; HUMAN; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; MORTALITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN QUALITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY DISEASE; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS;

EID: 84896992406     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.896741     Document Type: Review

References (144)

1. World Health Organization, World Heart Federation and World Stroke Organization. Global Atlas on cardiovascular disease prevention and control. WHO Press; Geneva, Switzerland: 2011
2. World Health Organization. Global status report on noncommunicable diseases 2010. WHO Press; Geneva, Switzerland: 2011
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
4. Rea TD, Pearce RM, Raghunathan TE, et al. Incidence of out-of-hospital cardiac arrest. Am J Cardiol 2004;93:1455-60
5. Soloff LA. Intermediate lipoproteins, atherosclerosis, and Gofman. Circulation 1998;97:708
6. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
7. Despres JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000;153:263-72
8. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003;41:567-77
9. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 2008;29:2625-33
10. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012;14: 1-10
11. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
12. Marcel YL, Weech PK, Nguyen TD, et al. Apolipoproteins as the basis for heterogeneity in high-density lipoprotein2 and high-density lipoprotein3. Studies by isoelectric focusing on agarose films. Eur J Biochem 1984;143:467-76
13. Gofman JW, Glazier F, Tamplin A, et al. Lipoproteins, coronary heart disease, and atherosclerosis. Physiol Rev 1954;34: 589-607
14. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34: 1345-53
15. Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68
16. Badellino KO, Rader DJ. The role of endothelial lipase in high-density lipoprotein metabolism. Curr Opin Cardiol 2004;19: 392-5
17. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011;57:1111-19
18. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-300
19. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: A potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010;18: 141-7
20. Bielicki JK, Zhang H, Cortez Y, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010;51:1496-503
21. Kypreos KE, Gkizas S, Rallidis LS, Karagiannides I. HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol 2013;85:1575-8
22. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365: 2255-67
23. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-60
24. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73
25. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99
26. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
27. Soutar AK, Garner CW, Baker HN, et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 1975;14: 3057-64
28. Chroni A, Liu T, Gorshkova I, et al. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem 2003;278: 6719-30
29. Fitzgerald ML, Morris AL, Chroni A, et al. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J Lipid Res 2004;45:287-94
30. Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005;1:121-31
31. Gelissen IC, Harris M, Rye KA, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006;26: 534-40
32. Zannis VI, Kardassis D, Zanni EE. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes. Adv Hum Genet 1993;21:145-319
33. Allan CM, Walker D, Segrest JP, Taylor JM. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics 1995;28: 291-300
34. Brewer HB Jr, Fairwell T, LaRue A, et al. The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun 1978;80:623-30
35. Nolte RT, Atkinson D. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J 1992;63:1221-39
36. Borhani DW, Rogers DP, Engler JA, Brouillette CG. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 1997;94: 12291-6
37. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005;115:1333-42
38. Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006;116:1052-62
39. Liadaki KN, Liu T, Xu S, et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 2000;275:21262-71
40. Moestrup SK, Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000;11:133-40
41. Smith BT, Mussell JC, Fleming PA, et al. Targeted disruption of cubilin reveals essential developmental roles in the structure and function of endoderm and in somite formation. BMC Dev Biol 2006;6:30
42. Brewer HB Jr, Lux SE, Ronan R, John KM. Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proc Natl Acad Sci USA 1972;69: 1304-8
43. Silva RA, Schneeweis LA, Krishnan SC, et al. The structure of apolipoprotein A-II in discoidal high density lipoproteins. J Biol Chem 2007;282:9713-21
44. Ko KW, Paul A, Ma K, et al. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res 2005;46: 2586-94
45. Chen CH, Albers JJ. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. Biochim Biophys Acta 1985;836: 279-85
46. Jackson RL, Sparrow JT, Baker HN, et al. The primary structure of apolopoproteinserine. J Biol Chem 1974;249:5308-13
47. Jong MC, Gijbels MJ, Dahlmans VE, et al. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest 1998;101: 145-52
48. Jackson RL, Baker HN, Gilliam EB, Gotto AM Jr. Primary structure of very low density apolipoprotein C-II of human plasma. Proc Natl Acad Sci USA 1977;74: 1942-5
49. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999;19:472-84
50. Brewer HB Jr, Shulman R, Herbert P, et al. The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. J Biol Chem 1974;249:4975-84
51. Kypreos KE. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. Biochemistry 2008;47: 10491-502
52. Remaley AT, Thomas F, Stonik JA, et al. Synthetic amphipathic helical peptide mediated efflux of lipid from cells by an ABCA1-dependent and an ABCA1- independent pathway. J Lipid Res 2003;44: 828-36
53. Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. J Clin Invest 1983;71:1023-31
54. Zannis VI, Kypreos KE, Chroni A, et al. In: Loscalzo J, editor. Molecular mechanisms of atherosclerosis. Taylor & Francis; New York, NY, USA: 2004. p. 111-74
55. Kowal RC, Herz J, Weisgraber KH, et al. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990;265:10771-9
56. Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J 2007;403: 359-67
57. Gelissen IC, Hochgrebe T, Wilson MR, et al. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: A potential anti-atherogenic function? Biochem J 1998;331(Pt 1):231-7
58. Brunzell JD, Deeb SS. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors. The metabolic & molecular bases of inherited disease. McGraw-Hill; New York, NY, USA: 2001. p. 2789-816
59. Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer HB Jr. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease. McGraw-Hill; New York, NY, USA: 2001. p. 2817-34
60. Tall AR, Breslow JL, Rubin EM. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors. The metabolic & molecular bases of inherited disease. McGraw-Hill; New York, NY, USA: 2001. p. 2915-36
61. Marais AD. Therapeutic modulation of low-density lipoprotein size. Curr Opin Lipidol 2000;11:597-602
62. Annema W, Tietge UJ. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep 2011;13: 257-65
63. Zambon A, Austin MA, Brown BG, et al. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993;13:147-53
64. Jaye M, Lynch KJ, Krawiec J, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999;21: 424-8
65. Hirata K, Dichek HL, Cioffi JA, et al. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem 1999;274:14170-5
66. Rader DJ, Jaye M. Endothelial lipase: A new member of the triglyceride lipase gene family. Curr Opin Lipidol 2000;11:141-7
67. Ma K, Cilingiroglu M, Otvos JD, et al. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA 2003;100: 2748-53
68. Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003;111:347-55
69. Assmann G, von Eckardstein A, Brewer HB. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. McGraw-Hill; New York, NY, USA: 2001. p. 2937-60
70. Funke H, von Eckardstein A, Pritchard PH, et al. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci USA 1991;88: 4855-9
71. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987;327:632-4
72. Chajek T, Fielding CJ. Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc Natl Acad Sci USA 1978;75:3445-9
73. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002;13:135-9
74. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001;155: 269-81
75. Cheung MC, Vaisar T, Han X, et al. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry 2010;49:7314-22
76. Oram JF, Wolfbauer G, Tang C, et al. An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J Biol Chem 2008;283: 11541-9
77. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, et al. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010; 208(1):3-9
78. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998;18:297-330
79. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 2002;161: 245-54
80. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl):S11-20
81. Herscovitz H, Ronen I, Bilu S, Tietz A. Bile acid synthesis from HDL cholesterol and cholesterol ester by cultured chick embryo hepatocytes. Biochim Biophys Acta 1986;878:426-34
82. Serhan N, Cabou C, Verdier C, et al. Chronic pharmacological activation of P2Y13 receptor in mice decreases HDLcholesterol level by increasing hepatic HDL uptake and bile acid secretion. Biochim Biophys Acta 2013;1831:719-25
83. Jolley CD, Dietschy JM, Turley SD. Induction of bile acid synthesis by cholesterol and cholestyramine feeding is unimpaired in mice deficient in apolipoprotein AI. Hepatology 2000;32: 1309-16
84. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5
85. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284: 1365-8
86. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-53
87. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41: 1495-508
88. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88: 2039-46
89. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-94
90. Navab M, Reddy S, Van Lenten BJ, et al. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2008;50:S145-9
91. Sviridov D, Mukhamedova N, Remaley AT, et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008;15:52-62
92. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72
93. Norata GD, Callegari E, Marchesi M, et al. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 2005;111: 2805-11
94. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004;109:2116-22
95. Jambou D, Dejour N, Bayer P, et al. Effect of human native low-density and high-density lipoproteins on prostaglandin production by mouse macrophage cell line P388D1: possible implications in pathogenesis of atherosclerosis. Biochim Biophys Acta 1993;1168:115-21
96. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8
97. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000;14:2032-9
98. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 2001;104:2498-502
99. Yin K, Liao DF, Tang CK. ATP-binding membrane cassette transporter A1 (ABCA1): A possible link between inflammation and reverse cholesterol transport. Mol Med 2010;16:438-49
100. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010;30: 139-43
101. Angeli V, Llodra J, Rong JX, et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004;21:561-74
102. Gong M, Wilson M, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003;111:1579-87
103. Nofer JR, van der GM, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-81
104. Oslakovic C, Krisinger MJ, Andersson A, et al. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem 2009;284:5896-904
105. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006;98:63-72
106. Tso C, Martinic G, Fan WH, et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006;26:1144-9
107. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336-45
108. Karavia EA, Papachristou DJ, Liopeta K, et al. Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice. Mol Med 2012;18:901-12
109. Han R, Lai R, Ding Q, et al. Apolipoprotein A-I stimulates AMPactivated protein kinase and improves glucose metabolism. Diabetologia 2007;50: 1960-8
110. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010;30: 1642-8
111. Fryirs M, Barter PJ, Rye KA. Cholesterol metabolism and pancreatic beta-cell function. Curr Opin Lipidol 2009;20: 159-64
112. Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010;21:178-85
113. Fan J, Wang J, Bensadoun A, et al. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA 1994;91:8724-8
114. Busch SJ, Barnhart RL, Martin GA, et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994;269:16376-82
115. Barbagallo CM, Fan J, Blanche PJ, et al. Overexpression of human hepatic lipase and ApoE in transgenic rabbits attenuates response to dietary cholesterol and alters lipoprotein subclass distributions. Arterioscler Thromb Vasc Biol 1999;19: 625-32
116. Jiang X, Francone OL, Bruce C, et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996;98: 2373-80
117. Jaari S, Van Dijk KW, Olkkonen VM, et al. Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta- HDL generation. Comp Biochem Physiol B Biochem Mol Biol 2001;128:781-92
118. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999;103: 907-14
119. Qin S, Kawano K, Bruce C, et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res 2000;41:269-76
120. Wang N, Arai T, Ji Y, et al. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem 1998;273: 32920-6
121. Ji Y, Wang N, Ramakrishnan R, et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 1999;274:33398-402
122. Arai T, Wang N, Bezouevski M, et al. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999;274:2366-71
123. Ueda Y, Gong E, Royer L, et al. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem 2000;275: 20368-73
124. Holm TM, Braun A, Trigatti BL, et al. Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood 2002;99:1817-24
125. Trigatti B, Rayburn H, Vinals M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999;96:9322-7
126. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62
127. Delalla OF, Elliott HA, Gofman JW. Ultracentrifugal studies of high density serum lipoproteins in clinically healthy adults. Am J Physiol 1954;179:333-7
128. Harman NL, Griffin BA, Davies IG. Separation of the principal HDL subclasses by iodixanol ultracentrifugation. J Lipid Res 2013;54:2273-81
129. Gidez LI, Miller GJ, Burstein M, et al. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982;23:1206-23
130. Park YB, Jahani M, Lacko AG. Isolation of high-density lipoproteins by immunoaffinity column chromatography from hog plasma. Comp Biochem Physiol B 1985;82:529-33
131. Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 2010;9:5239-49
132. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2670-6
133. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN. Gradient gel electrophoretic separation of LDL and HDL subclasses on BioRad Mini Protean II and size phenotyping in healthy Macedonians. Clin Chim Acta 2002;317:119-23
134. Gordon SM, Deng J, Tomann AB, et al. Multi-dimensional co-separation analysis reveals protein-protein interactions defining plasma lipoprotein subspecies. Mol Cell Proteomics 2013;12:3123-34
135. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-9
136. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. Lancet 2008;372: 224-33
137. Kavo AE, Rallidis LS, Sakellaropoulos GC, et al. Qualitative characteristics of HDL in young patients of an acute myocardial infarction. Atherosclerosis 2012;220:257-64
138. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDLcholesterol. J Lipid Res 2010;51:2032-57
139. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 2012;380: 572-80
140. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:2524-32
141. Roma P, Gregg RE, Meng MS, et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A- IMilano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993;91:1445-52
142. Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 2006;101:1727-32
143. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010;21:312-18
144. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters. relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009;29(6):870-6